시장보고서

상품코드

1935137

신경내분비암 치료 시장 : 약제 클래스별, 적응증 유형별, 최종사용자별, 투여 경로별, 유통경로별, 지역별

Neuroendocrine Carcinoma Treatment Market, By Drug Class, By Indication Type, By End User, By Route of Administration, By Distribution Channel, By Geography

발행일: 2026년 01월 | 리서치사:

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경내분비암 치료 시장은 2026년에 23억 5,000만 달러로 추정되며, 2033년까지 40억 8,000만 달러에 달할 것으로 예측됩니다. 2026-2033년에 CAGR 8.2%로 성장할 전망입니다.

리포트 내용		리포트 상세
기준연도 :	2025년	2026년 시장 규모 :	23억 5,000만 달러
과거 데이터 대상 기간 :	2020-2024년	예측 기간 :	2026-2033년
예측 기간인 2026-2033년의 CAGR :	8.20%	2033년의 예측치 :	40억 8,000만 달러

세계 신경내분비암 치료 시장은 종양 치료 분야에서 중요한 부분을 차지하고 있으며, 신경내분비종양(NET) 및 신경내분비암(NEC) 진단을 받은 환자들의 복잡한 임상적 요구를 충족시키고 있습니다. 드물지만 점차 인지도가 높아지고 있는 이 악성 종양은 소화관, 췌장, 폐, 기타 해부학적 부위를 포함한 다양한 장기 시스템에 분포하는 신경내분비세포에서 발생합니다. 신경내분비암은 이질성, 분화도의 다양성, 다양한 임상 증상이 특징이며, 외과적 개입, 전신 치료, 분자 표적 치료를 결합한 첨단 치료 접근법을 필요로 합니다.

시장에는 소마토스타틴 유사체, 표적치료제, 화학요법, 펩티드 수용체 방사성 핵종 요법(PRRT), 새로운 면역치료 접근법 등 종합적인 치료법이 포함됩니다. 진단 기술의 발전, 종양 생물학에 대한 이해의 심화, 의료진의 인식 개선에 따라 신경내분비암의 식별과 치료는 크게 발전하고 있습니다. 증가하는 이환율과 혁신적인 치료 전략으로 인한 생존율 향상은 시장에 큰 성장 기회를 가져다주고 있습니다. 이 전문 치료 시장은 제약사로부터 막대한 투자를 유치하고 있으며, 특정 종양 특성 및 환자 프로파일에 맞는 새로운 치료 패러다임과 맞춤형 의료 접근법 개발을 촉진하고 있습니다.

시장 역학

세계 신경내분비암 치료 시장은 진단 기술의 발전과 의료진의 임상적 인식 향상으로 인한 신경내분비종양 발생률 증가를 비롯한 여러 강력한 시장 성장 촉진요인에 의해 주도되고 있습니다. 첨단 영상 진단 기술, 분자진단, 바이오마커의 식별으로 조기 발견 능력이 크게 향상되어 치료적 개입이 필요한 환자층이 확대되고 있습니다. 제약사들의 연구개발 투자 증가는 기존 화학요법 대비 효능을 높이고 부작용을 줄인 표적치료제, 면역치료제, 정밀의료 접근법 등 혁신적인 치료법의 도입을 가속화하고 있습니다.

그러나 시장에는 큰 억제요인도 존재합니다. 주요 요인은 신경내분비암의 희소성으로 인해 임상시험 대상 환자 수가 제한되어 있고, 새로운 치료법의 규제 당국 승인 획득에 어려움을 겪고 있습니다. 특히 신규 표적치료제와 펩티드 수용체 방사성 핵종 치료(PRRT)의 높은 치료비는 의료 시스템과 환자 모두에게 심각한 경제적 부담을 초래하고 시장 접근성을 제한할 수 있습니다.

또한 신경내분비종양의 이질성은 치료의 표준화를 복잡하게 만들고, 1차 진료의사의 인식이 제한적이기 때문에 진단이 늦어지거나 치료 결과를 최적화하지 못할 수 있습니다. 이러한 과제가 있는 반면, 개발중인 약물 파이프라인의 확대, 병용요법 접근법의 확산, 종양 유전자 정보 및 환자별 요인에 기반한 맞춤 치료 전략에 대한 관심이 높아지면서 큰 기회가 창출되고 있습니다. 개발도상국의 발병률 증가와 더불어 의료 인프라 개선 및 의료비 증가가 맞물려 신경내분비암 치료의 미충족 수요를 해결하고자 하는 제약사들에게 시장 확대의 큰 기회가 되고 있습니다.

본 조사의 주요 특징

세계의 신경내분비암 치료 시장에 대해 조사 분석했으며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 예측한 보고서입니다.
또한 다양한 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보를 제공합니다.
이 보고서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 세계 신경내분비암 치료 시장의 주요 업체를 프로파일링합니다.
이 보고서는 마케팅 담당자 및 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
이 세계 신경내분비암 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 신경내분비암 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 2.35 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.20%	2033 Value Projection:	USD 4.08 Bn

The global neuroendocrine carcinoma treatment market represents a critical segment within the oncology therapeutics landscape, addressing the complex clinical needs of patients diagnosed with neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These rare but increasingly recognized malignancies arise from neuroendocrine cells distributed throughout various organ systems, including the gastrointestinal tract, pancreas, lungs, and other anatomical sites. Neuroendocrine carcinomas are characterized by their heterogeneous nature, varying degrees of differentiation, and diverse clinical presentations, necessitating sophisticated treatment approaches that combine surgical interventions, systemic therapies, and targeted molecular treatments.

The market encompasses a comprehensive range of therapeutic modalities including somatostatin analogs, targeted therapy agents, chemotherapy regimens, peptide receptor radionuclide therapy (PRRT), and emerging immunotherapeutic approaches. With advancing diagnostic capabilities, improved understanding of tumor biology, and growing awareness among healthcare professionals, the identification and treatment of neuroendocrine carcinomas have significantly evolved. The increasing incidence rates, coupled with enhanced survival outcomes through innovative treatment strategies, drives substantial market growth opportunities. This specialized therapeutic market continues to attract significant pharmaceutical investment, fostering the development of novel treatment paradigms and personalized medicine approaches tailored to specific tumor characteristics and patient profiles.

Market Dynamic

The global neuroendocrine carcinoma treatment market is propelled by several robust drivers, including the rising incidence of neuroendocrine tumors worldwide, attributed to improved diagnostic techniques and increased clinical awareness among healthcare professionals. Advanced imaging technologies, molecular diagnostics, and biomarker identification have significantly enhanced early detection capabilities, leading to expanded patient populations requiring therapeutic intervention. The growing investment in research and development by pharmaceutical companies has accelerated the introduction of innovative treatment modalities, including targeted therapies, immunotherapies, and precision medicine approaches that offer improved efficacy and reduced adverse effects compared to conventional chemotherapy regimens.

However, the market faces considerable restraints, primarily stemming from the rare nature of neuroendocrine carcinomas, which limits patient populations for clinical trials and creates challenges in achieving regulatory approvals for new treatments. High treatment costs, particularly for novel targeted therapies and peptide receptor radionuclide therapy, create significant financial burdens for healthcare systems and patients, potentially limiting market accessibility.

Additionally, the heterogeneous nature of neuroendocrine tumors complicates treatment standardization, while limited awareness among primary care physicians may result in delayed diagnoses and suboptimal treatment outcomes. Despite these challenges, substantial opportunities emerge from the expanding pipeline of investigational drugs, increasing adoption of combination therapy approaches, and growing focus on personalized treatment strategies based on tumor genetics and patient-specific factors. The rising prevalence in developing economies, coupled with improving healthcare infrastructure and increasing healthcare expenditure, presents significant market expansion opportunities for pharmaceutical companies seeking to address unmet medical needs in neuroendocrine carcinoma treatment.

Key Features of the Study

This report provides in-depth analysis of the global neuroendocrine carcinoma treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neuroendocrine carcinoma treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Ipsen Pharma, Pfizer Inc, Bristol Myers Squibb, Eli Lilly and Company, Merck & Co, Amgen, Boehringer Ingelheim, Teva Pharmaceutical Industries, Hutchison China MediTech, Exelixis Inc, Chiasma Inc, Advanced Accelerator Applications (Novartis Radioligand), Progenics Pharmaceuticals, and AbbVie Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global neuroendocrine carcinoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuroendocrine carcinoma treatment market

Market Segmentation

Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Somatostatin Analogs
- Chemotherapeutic Agents
- Targeted Therapy Drugs
- Immunomodulatory Drugs
- Peptide Receptor Radionuclide Therapy (PRRT)
- Hormonal Agents
Indication Type Insights (Revenue, USD Bn, 2021 - 2033)
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Pulmonary Neuroendocrine Tumors
- Thyroid Neuroendocrine Tumors
- Others (e.g. Adrenal Gland Neuroendocrine Tumors)
End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Cancer Treatment Centers
- Ambulatory Surgery Centers
- Home Care
- Research Institutes
Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novartis AG
- Ipsen Pharma
- Pfizer Inc
- Bristol Myers Squibb
- Eli Lilly and Company
- Merck & Co
- Amgen
- Boehringer Ingelheim
- Teva Pharmaceutical Industries
- Hutchison China MediTech
- Exelixis Inc
- Chiasma Inc
- Advanced Accelerator Applications (Novartis Radioligand)
- Progenics Pharmaceuticals
- AbbVie Inc

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Neuroendocrine Carcinoma Treatment Market, By Drug Class
- Global Neuroendocrine Carcinoma Treatment Market, By Indication Type
- Global Neuroendocrine Carcinoma Treatment Market, By End User
- Global Neuroendocrine Carcinoma Treatment Market, By Route of Administration
- Global Neuroendocrine Carcinoma Treatment Market, By Distribution Channel
- Global Neuroendocrine Carcinoma Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Neuroendocrine Carcinoma Treatment Market, By Drug Class, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Somatostatin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Chemotherapeutic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Targeted Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Immunomodulatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Peptide Receptor Radionuclide Therapy (PRRT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Hormonal Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Neuroendocrine Carcinoma Treatment Market, By Indication Type, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Pulmonary Neuroendocrine Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Thyroid Neuroendocrine Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Others (e.g. Adrenal Gland Neuroendocrine Tumors)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Neuroendocrine Carcinoma Treatment Market, By End User, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Ambulatory Surgery Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Home Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Neuroendocrine Carcinoma Treatment Market, By Route of Administration, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

8. Global Neuroendocrine Carcinoma Treatment Market, By Distribution Channel, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

9. Global Neuroendocrine Carcinoma Treatment Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BristolMyers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hutchison China MediTech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Exelixis Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Chiasma Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Advanced Accelerator Applications (Novartis Radioligand)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Progenics Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

11. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

12. References and Research Methodology

References
Research Methodology
About us

신경내분비암 치료 시장 : 약제 클래스별, 적응증 유형별, 최종사용자별, 투여 경로별, 유통경로별, 지역별

Neuroendocrine Carcinoma Treatment Market, By Drug Class, By Indication Type, By End User, By Route of Administration, By Distribution Channel, By Geography

목차

제1장 조사 목적과 전제조건

제2장 시장 범위

제3장 시장 역학, 규제 및 동향 분석

제4장 세계의 신경내분비암 치료 시장 : 약제 클래스별, 2021-2033년

제5장 세계의 신경내분비암 치료 시장 : 적응증 유형별, 2021-2033년

제6장 세계의 신경내분비암 치료 시장 : 최종사용자별, 2021-2033년

제7장 세계의 신경내분비암 치료 시장 : 투여 경로별, 2021-2033년

제8장 세계의 신경내분비암 치료 시장 : 유통경로별, 2021-2033년

제9장 세계의 신경내분비암 치료 시장 : 지역별, 2021-2033년

제10장 경쟁 구도

제11장 애널리스트의 권장사항

제12장 참고 문헌 및 조사 방법